Mirum Pharmaceuticals Inc (MIRM)

$32

-0.07

(-0.22%)

Market is closed - opens 8 PM, 04 Dec 2023

Performance

  • $31.44
    $32.49
    $32.00
    downward going graph

    1.75%

    Downside

    Day's Volatility :3.23%

    Upside

    1.51%

    downward going graph
  • $17.49
    $33.39
    $32.00
    downward going graph

    45.34%

    Downside

    52 Weeks Volatility :47.62%

    Upside

    4.16%

    downward going graph

Returns

PeriodMirum Pharmaceuticals Inc
3 Months
15.86%
6 Months
21.53%
1 Year
69.4%
3 Years
33.89%

Highlights

Market Capitalization
1.5B
Book Value
$5.78
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-4.27
Wall Street Target Price
54.7
Profit Margin
-113.45%
Operating Margin TTM
-52.69%
Return On Assets TTM
-13.64%
Return On Equity TTM
-74.91%
Revenue TTM
144.7M
Revenue Per Share TTM
3.76
Quarterly Revenue Growth YOY
154.1%
Gross Profit TTM
64.7M
EBITDA
-104.2M
Diluted Eps TTM
-4.27
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.47
EPS Estimate Next Year
-0.23
EPS Estimate Current Quarter
-0.65
EPS Estimate Next Quarter
-0.37

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Mirum Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
11
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 70.94%

Current $32.00
Target $54.70

Technicals Summary

Sell

Neutral

Buy

Mirum Pharmaceuticals Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin

Institutional Holdings

  • Bvf Inc

    9.37%
  • Eventide Asset Management, LLC

    8.49%
  • NEA Management Company, LLC

    4.69%
  • BlackRock Inc

    4.36%
  • HHG PLC

    4.13%
  • Rock Springs Capital Management LP

    3.91%

Corporate Announcements

  • Mirum Pharmaceuticals Inc Earnings

    Mirum Pharmaceuticals Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

mirum pharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. its lead product candidate is maralixibat, an investigational oral drug that is in phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of alagille syndrome and biliary atresia disease. the company is also develops volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. mirum pharmaceuticals, inc. was founded in 2018 and is headquartered in foster city, california.

Organization
Mirum Pharmaceuticals Inc
Employees
249
CEO
Mr. Christopher Peetz
Industry
Health Technology

FAQs